Brought to you by 
Wellcome licenses Vertex HIV protease inhibitors
30 May 2000
Executive Summary
Wellcome has licensed US & European rights to Vertex's HIV protease inhibitors, the most advanced of which are currently in preclinical studies. The transaction is worth a potential $42 million to Vertex in initial fees and research payments.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com